The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b dose extension study of a next-generation anti-CD47 monoclonal antibody IMC-002 combined with lenvatinib in patients with advanced hepatocellular carcinoma (HCC).
 
Jung Yong Hong
Honoraria - AstraZeneca; AstraZeneca; Dong-A Socio
Consulting or Advisory Role - AstraZeneca; Eisai
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
Speakers' Bureau - Bayer
 
Minsuk Kwon
Consulting or Advisory Role - ImmuneOncia
 
Sung Young Lee
Employment - ImmuneOncia
Leadership - ImmuneOncia
Stock and Other Ownership Interests - ImmuneOncia
Patents, Royalties, Other Intellectual Property - ImmuneOncia Therapeutics Inc.
 
Subin Lee
Employment - ImmuneOncia
 
Hwi-yeol Yun
Consulting or Advisory Role - ImmuneOncia
 
Soohyun Hwang
Employment - Lunit
Leadership - Lunit
 
Woochan Hwang
Employment - Lunit
Stock and Other Ownership Interests - Lunit
 
Sung Ho Kim
Employment - ImmuneOncia
Leadership - ImmuneOncia
Stock and Other Ownership Interests - ImmuneOncia
 
Heung Tae Kim
Employment - ImmuneOncia
Leadership - ImmuneOncia
Stock and Other Ownership Interests - ImmuneOncia